Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belgian Precision 2: olaparib in advanced homologous recombination gene-mutated cancers
2024-518522-32-00Phase 2Completed
- Sponsor
- Belgian Society of Medical Oncology
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib in Nonhematologic neoplasms and None, sponsored by Belgian Society of Medical Oncology. Primary endpoints: Response rate according to RECIST 1.1 and Response duration. Started Oct 2024; status: completed.
02
Drugs
olaparib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2024-518522-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518522-32-00.